VIEWRAY

After 8 years of clinical use, nearly 27,000 patients have been treated on MRIdian. Today, over 50 hospitals worldwide have built successful MRIdian programs to expand cancer care with many centers investing in additional systems to meet patient demand. Research how MRIdian offers personalized cancer treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers... MRIdian is the first MR-guided radiotherapy system with peer-reviewed evidence demonstrating reduced side effects and extended survival by decreasing treatment volumes and delivering ablative doses. Learn the impact of MRIdian through stories told firsthand by patients and physicians... MRIdian allows oncologists to visualize, adapt, and target using anatomical detail that is simply unavailable with conventional IGRT technologies.

Also known as: ViewRay Technologies, ViewRay Technologies, Inc., ViewRay®, Inc.

Primary location: Mountain View United States